Facebook
Twitter
LinkedIn
Forward
Mass General Cancer Center Practice-Changing Updates in Hematologic Malignancies 2024
Please note, access to symposium recordings is included with registration.
Access will be available for 30 days post event.
With several new drug and cellular therapies as well as an expansion of our understanding of the biologic heterogeneity of hematologic malignancies, there is a need for ongoing education in the area of hematologic malignancies. This interactive webinar series will focus on current best practices, and how those are evolving based on major updates in the biology, diagnosis, and management of hematologic malignancies. Attendee interaction is encouraged and promoted through the designated time for audience questions at the end of each webinar. Each 90-minute webinar will have two talks followed by discussion and audience Q&A. Presenters will include internationally-known disease experts from Mass General Cancer Center covering high-yield practice-changing updates in cellular therapies, transplant, myeloma, leukemia, and lymphoma.
Target Audience
This activity is intended for physicians, nurses, pharmacists, other members of healthcare team (regional) with specialties such as general practice, hematology, hematology/oncology, medical oncology, primary care, and radiation oncology.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe new therapies available for hematologic malignancies.
- Discuss practice-changing updates in the management of hematologic malignancies Consider new concepts in palliative care and survivorship.
- Determine appropriate timing to consider transplant evaluation and cellular therapy referral for hematologic malignancies.
- Discuss latest and most promising disease-specific treatment options amongst the team to improve patient outcomes.
FUNDING
Mass General Cancer Center Practice-Changing Updates in Hematologic Malignancies 2024 has received support in the form of an educational grant from the following companies:
AbbVie Inc.
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Incyte Corporation
Additional Information
Massachusetts General Hospital Cancer Center & Mass General Brigham
February 1, 2024 - Lymphoma
Speakers: Jake Soumerai, MD & Erika Haydu, MD, PhD
February 26, 2024 - Cellular Therapies
Speakers: Matthew Frigault, MD & P. Connor Johnson, MD
March 27, 2024 - Myeloma
Speakers: Andrew Yee, MD & Diana Cirstea, MD
April 23, 2024 - Leukemia
Speakers: Gaby Hobbs, MD & Andrew Brunner, MD
May 21, 2024 - Transplants
Speakers: Zachariah DeFilipp, MD & Richard Newcomb, MD
Course Director:
P. Connor Johnson, MD
Hematology/Oncology, Massachusetts General Hospital Cancer Center
Instructor in Medicine, Harvard Medical School
Faculty:
Andrew Brunner, MD
Assistant in Medicine, Center for Leukemia, Massachusetts General Hospital;
Assistant Professor, Medicine, Harvard Medical School
Diana Cirstea, MD
Attending Physician, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Zach DeFilipp, MD
Director, BMT Clinical Research, Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine, Harvard Medical School
Matt Frigault, MD
Administrative Director, Cellular Therapy Service, Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine, Harvard Medical School
Erika Haydu, MD, PhD
Assistant in Medicine, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Gaby Hobbs, MD
Clinical Director, Leukemia Service, Massachusetts General Hospital Cancer Center
Assistant in Medicine, Harvard Medical School
Richard Newcomb, MD
Instructor of Medicine, Harvard Medical School
Assistant Physician, Massachusetts General Hospital
Jake Soumerai, MD
Clinical Investigator in Lymphoma, Medicine, Massachusetts General Hospital
Assistant Professor, Medicine, Harvard Medical School
Andrew Yee, MD
Clinical Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditsTM
Mass General Brigham designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Mass General Brigham designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Pharmacy
This activity provides 1.5 contact hours (1.5 CEUs) of continuing education credit. ACPE Universal Activity Number (UAN): JA0007437-0000-24-001-L01-P
Pharmacy Technicians
This activity provides 1.5 contact hours (1.5 CEUs) of continuing education credit. ACPE Universal Activity Number (UAN): JA0007437-0000-24-001-L01-T